- enVVeno Medical's VenoValve to be showcased at Charing Cross Symposium in London, April 23-25, 2025.
- Dr. David Dexter to present on the invasive correction of deep venous reflux on April 24, 2025.
- A decision on the FDA's pre-market authorization for VenoValve is expected in the second half of 2025.
enVVeno Medical Corporation (NASDAQ:NVNO) has announced that its innovative VenoValve® will be a focal point of the 47th Annual Charing Cross Symposium in London, scheduled from April 23-25, 2025. Dr. David Dexter from Sentara Hospital and Eastern Virginia Medical School is set to deliver a presentation on April 24, titled "Progress to date and future prospects for invasive correction of deep venous reflux."
The VenoValve is positioned as a potential first-in-class surgical replacement venous valve engineered for patients suffering from severe deep venous Chronic Venous Insufficiency (CVI). The U.S. healthcare market shows promising potential, with estimates suggesting approximately 2.5 million new patients annually could benefit from the VenoValve. enVVeno Medical has submitted a pre-market authorization (PMA) application to the U.S. FDA, and a decision is anticipated in the latter half of 2025. Successful approval could significantly impact treatment strategies for CVI, a condition currently lacking effective treatment options.
Chronic Venous Insufficiency is a debilitating condition, often a consequence of deep vein thromboses, which leads to improper blood flow and pooling in the legs. This results in increased venous pressure and symptoms such as leg swelling, pain, and in severe cases, recurrent venous ulcers. The absence of effective treatment heightens the significance of the VenoValve, which is designed to act as a one-way valve to facilitate blood flow back to the heart, potentially alleviating symptoms and improving patient quality of life.
enVVeno Medical, headquartered in Irvine, California, remains committed to advancing care standards for deep venous diseases through its pioneering bioprosthetic solutions. The expectation surrounding the FDA's PMA decision later in 2025 underscores the company's innovative trajectory in the medical device industry.
